Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD33 Positive Acute Myelogenous Leukemia”

19 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 19 results

Early research (Phase 1)Study completedNCT00002890
What this trial is testing

Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

Who this might be right for
LeukemiaMyelodysplastic Syndromes
Memorial Sloan Kettering Cancer Center 24
Not applicableNo Longer AvailableNCT02312037
What this trial is testing

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

Who this might be right for
CD33 Positive Acute Myelogenous Leukemia
Pfizer
Early research (Phase 1)UnknownNCT02799680
What this trial is testing

Allogeneic CART-33 for Relapsed/Refractory CD33+ AML

Who this might be right for
Relapsed and/or Refractory CD33+ AML
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences 12
Testing effectiveness (Phase 2)Study completedNCT00233909
What this trial is testing

A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

Who this might be right for
Leukemia, Myeloid
Kanisa Pharmaceuticals 55
Very early researchUnknownNCT04156256
What this trial is testing

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Who this might be right for
Hematologic MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes+2 more
iCell Gene Therapeutics 20
Early research (Phase 1)Not Yet RecruitingNCT07538713
What this trial is testing

Functionally Optimized CD33 CAR-T Cell Therapy Targeting Recurrent/Refractory Acute Myeloid Leukemia

Who this might be right for
CAR T Cell TherapyCD33 Positive Acute Myelogenous Leukemia
Qi deng 18
Early research (Phase 1)Active Not RecruitingNCT03927261
What this trial is testing

PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Precigen, Inc 88
Not applicableApproved For MarketingNCT01869803
What this trial is testing

Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)+7 more
Wake Forest University Health Sciences
Testing effectiveness (Phase 2)Study completedNCT00014495
What this trial is testing

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Memorial Sloan Kettering Cancer Center 32
Large-scale testing (Phase 3)Study completedNCT00909168
What this trial is testing

Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
University Hospital, Udine, Italy 130
Testing effectiveness (Phase 2)UnknownNCT01864902
What this trial is testing

Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33

Who this might be right for
Relapsed Adult Myeloid LeukemiaChemotherapy Refractory Adult Myeloid Leukemia
Chinese PLA General Hospital 10
Early research (Phase 1)Ended earlyNCT00543972
What this trial is testing

Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

Who this might be right for
Myeloid Leukemia
Sanofi 12
Early research (Phase 1)Study completedNCT02674763
What this trial is testing

Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
ImmunoGen, Inc. 62
Early research (Phase 1)Study completedNCT04207190
What this trial is testing

Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Roswell Park Cancer Institute 24
Early research (Phase 1)Study completedNCT01902329
What this trial is testing

A Safety Study of SGN-CD33A in AML Patients

Who this might be right for
Acute Myelogenous LeukemiaAcute Myeloid LeukemiaAcute Promyelocytic Leukemia
Seagen Inc. 195
Post-approval studies (Phase 4)Study completedNCT03727750
What this trial is testing

Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML

Who this might be right for
ECGPharmacokineticsSafety
Pfizer 51
Testing effectiveness (Phase 2)WithdrawnNCT01548911
What this trial is testing

Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)+5 more
Wake Forest University Health Sciences
Very early researchUnknownNCT03795779
What this trial is testing

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Who this might be right for
Hematologic MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes+2 more
iCell Gene Therapeutics 20
Early research (Phase 1)Ended earlyNCT03126864
What this trial is testing

Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

Who this might be right for
Hematopoietic/Lymphoid CancerAcute Myeloid Leukemia
M.D. Anderson Cancer Center 11